Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Short Interest Update

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) was the target of a significant growth in short interest during the month of February. As of February 28th, there was short interest totalling 2,570,000 shares, a growth of 16.8% from the February 13th total of 2,200,000 shares. Approximately 2.5% of the company’s shares are sold short. Based on an average daily volume of 916,800 shares, the short-interest ratio is currently 2.8 days.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on the company. Canaccord Genuity Group cut Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, December 17th. Bernstein Bank dropped their price target on Regeneron Pharmaceuticals from $1,070.00 to $1,000.00 in a research note on Tuesday, February 4th. Citigroup reduced their price objective on shares of Regeneron Pharmaceuticals from $795.00 to $750.00 and set a “neutral” rating for the company in a research note on Tuesday, January 28th. Bank of America restated an “underperform” rating and issued a $565.00 price objective on shares of Regeneron Pharmaceuticals in a report on Tuesday, December 10th. Finally, Piper Sandler reduced their target price on Regeneron Pharmaceuticals from $1,195.00 to $1,013.00 and set an “overweight” rating for the company in a report on Monday, January 27th. One investment analyst has rated the stock with a sell rating, six have given a hold rating, seventeen have issued a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $973.13.

Hedge Funds Weigh In On Regeneron Pharmaceuticals

Several large investors have recently made changes to their positions in REGN. Pinney & Scofield Inc. purchased a new stake in shares of Regeneron Pharmaceuticals during the 4th quarter worth about $25,000. FSA Wealth Management LLC purchased a new position in Regeneron Pharmaceuticals during the third quarter worth approximately $26,000. OFI Invest Asset Management acquired a new stake in Regeneron Pharmaceuticals in the fourth quarter valued at approximately $28,000. Rakuten Securities Inc. raised its stake in shares of Regeneron Pharmaceuticals by 62.5% during the 4th quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company’s stock worth $28,000 after buying an additional 15 shares during the period. Finally, Avalon Trust Co purchased a new position in shares of Regeneron Pharmaceuticals during the 4th quarter valued at approximately $36,000. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Stock Down 0.1 %

Regeneron Pharmaceuticals stock traded down $0.85 during midday trading on Wednesday, hitting $664.11. 129,705 shares of the company’s stock were exchanged, compared to its average volume of 624,624. The company has a market cap of $72.60 billion, a PE ratio of 17.35, a P/E/G ratio of 2.34 and a beta of 0.27. The firm has a 50-day moving average of $692.84 and a two-hundred day moving average of $823.99. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.95 and a current ratio of 4.73. Regeneron Pharmaceuticals has a 12 month low of $642.00 and a 12 month high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $11.21 by $0.86. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The business had revenue of $3.79 billion for the quarter, compared to the consensus estimate of $3.76 billion. During the same period last year, the business posted $11.86 EPS. The business’s revenue was up 10.3% compared to the same quarter last year. As a group, analysts expect that Regeneron Pharmaceuticals will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, March 20th. Shareholders of record on Thursday, February 20th will be given a dividend of $0.88 per share. The ex-dividend date of this dividend is Thursday, February 20th. This represents a $3.52 dividend on an annualized basis and a yield of 0.53%. Regeneron Pharmaceuticals’s dividend payout ratio is currently 2.30%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.